within Pharmacolibrary.Drugs.ATC.P;

model P01CX04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.82,
    Cl             = 2.8333333333333332e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.066,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0010833333333333333,
    Tlag           = 13.8,            
    Vdp             = 3.35,
    k12             = 1.1,
    k21             = 1.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01CX04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Miltefosine is an alkylphosphocholine drug that was originally developed as an anticancer agent, but is currently approved and primarily used for the oral treatment of leishmaniasis (visceral, cutaneous, and mucocutaneous), a neglected tropical protozoal disease. It is the first effective oral drug for leishmaniasis and is included in WHO’s Essential Medicines List.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in adult Indian patients with visceral leishmaniasis following standard oral dosing.</p><h4>References</h4><ol><li><p>Ramisetty, BS, et al., &amp; Wang, MZ (2024). Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach. <i>Antimicrobial agents and chemotherapy</i> 68(7) e0032824–None. DOI:<a href=\"https://doi.org/10.1128/aac.00328-24\">10.1128/aac.00328-24</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38842325/\">https://pubmed.ncbi.nlm.nih.gov/38842325</a></p></li><li><p>Sindermann, H, &amp; Engel, J (2006). Development of miltefosine as an oral treatment for leishmaniasis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> 100 Suppl 1 S17–S20. DOI:<a href=\"https://doi.org/10.1016/j.trstmh.2006.02.010\">10.1016/j.trstmh.2006.02.010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16730362/\">https://pubmed.ncbi.nlm.nih.gov/16730362</a></p></li><li><p>Spadari, CC, et al., &amp; Ishida, K (2023). Oral delivery of brain-targeted miltefosine-loaded alginate nanoparticles functionalized with polysorbate 80 for the treatment of cryptococcal meningitis. <i>The Journal of antimicrobial chemotherapy</i> 78(4) 1092–1101. DOI:<a href=\"https://doi.org/10.1093/jac/dkad053\">10.1093/jac/dkad053</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36881722/\">https://pubmed.ncbi.nlm.nih.gov/36881722</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01CX04;
